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A B S T R A C T
Background
This is the first update of the original Cochrane Review published in 2013. The conclusions of this review have not changed from the
2013 publication. People with chronic non-cancer pain who are prescribed and are taking opioids can have a history of long-term,
high-dose opioid use without effective pain relief. In those without good pain relief, reduction of prescribed opioid dose may be the
desired and shared goal of both patient and clinician. Simple, unsupervised reduction of opioid use is clinically challenging, and very
difficult to achieve and maintain.
Objectives
To investigate the effectiveness of different methods designed to achieve reduction or cessation of prescribed opioid use for the
management of chronic non-cancer pain in adults compared to controls.
Search methods
For this update we searched CENTRAL, MEDLINE, and Embase in January 2017, as well as bibliographies and citation searches of
included studies. We also searched one trial registry for ongoing trials.
Selection criteria
Included studies had to be randomised controlled trials comparing opioid users receiving an intervention with a control group receiving
treatment as usual, active control, or placebo. The aim of the study had to include a treatment goal of dose reduction or cessation of
opioid medication.
Data collection and analysis
Two review authors independently extracted data and assessed risk of bias. We sought data relating to prescribed opioid use, adverse
events of opioid reduction, pain, and psychological and physical function. We planned to assess the certainty of the evidence using the
GRADE approach, however, due to the heterogeneity of studies, we were unable to combine outcomes in a meta-analysis and therefore
we did not assess the evidence with GRADE.
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Main results
Three studies are new to this update, resulting in five included studies in total (278 participants). Participants were primarily women
(mean age 49.63 years, SD = 11.74) with different chronic pain conditions. We judged the studies too heterogeneous to pool data
in a meta-analysis, so we have summarised the results from each study qualitatively. The studies included acupuncture, mindfulness,
and cognitive behavioral therapy interventions aimed at reducing opioid consumption, misuse of opioids, or maintenance of chronic
pain management treatments. We found mixed results from the studies. Three of the five studies reported opioid consumption at post-
treatment and follow-up. Two studies that delivered ’Mindfulness-Oriented Recovery Enhancement’ or ’Therapeutic Interactive Voice
Response’ found a significant difference between groups at post-treatment and follow-up in opioid consumption. The remaining study
found reduction in opioid consumption in both treatment and control groups, and between-group differences were not significant.
Three studies reported adverse events related to the study and two studies did not have study-related adverse events. We also found
mixed findings for pain intensity and physical functioning. The interventions did not show between-group differences for psychological
functioning across all studies. Overall, the risk of bias was mixed across studies. All studies included sample sizes of fewer than 100 and
so we judged all studies as high risk of bias for that category.
Authors’ conclusions
There is no evidence for the efficacy or safety of methods for reducing prescribed opioid use in chronic pain. There is a small number
of randomised controlled trials investigating opioid reduction, which means our conclusions are limited regarding the benefit of
psychological, pharmacological, or other types of interventions for people with chronic pain trying to reduce their opioid consumption.
The findings to date are mixed: there were reductions in opioid consumption after intervention, and often in control groups too.
P L A I N L A N G U A G E S U M M A R Y
Reducing prescribed opioid use in adults with chronic non-cancer pain
Bottom line
Based on the available evidence, we do not know the best method of reducing opioids in adults with chronic pain conditions. We found
mixed results from a small number of studies included in this review.
Background
This is an updated review. The first review was published in 2013. About one in five adults suffer from moderate or severe chronic pain
that is not caused by cancer. Some people with this type of pain are treated with opioids (typically with drugs such as morphine, codeine,
oxycodone, fentanyl, or buprenorphine, either as tablets or as patches placed on the skin). It is not unusual for this medication to be
ineffective or to stop working over time, and, sometimes, effective pain relief is not achieved despite doses being increased. Stopping
using opioid drugs is not easy, especially when they have been used for some time, because stopping abruptly can cause unpleasant side
effects.This review looked for high-quality studies (randomised controlled trials) of treatments to help adults safely stop taking opioids
prescribed for their pain.
Study characteristics
We searched for studies up to January 2017. We found five studies, and they investigated 278 people. Most people included in the
studies were women, who were around 50 years of age, and reported a mixture of chronic pain conditions (e.g. headache, back pain,
muscle pain). The studies included acupuncture, mindfulness, and cognitive behavioral therapy as strategies to decrease the amount of
opioids taken by adults with chronic pain.
Key results
No conclusions can be drawn from this small amount of information. Therefore, it is not clear whether these treatments decrease
the amount of opioids in adults with chronic pain (primary outcome) or reduce pain intensity, physical ability or mood (secondary
outcomes). Three studies did include negative effects of their treatment, and two reported that the participants did not have anything
negative happen to them because of the trial they were in. Non-randomised studies, not included in this review, do indicate that for
many people intensive rehabilitation packages may bring about major reduction in opioid use. Reducing prescribed opioid use in
chronic non-cancer pain is an important topic in need of more systematic research.
Quality of the evidence
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We were not able to judge the quality of evidence included in this review because the studies were so different and could not be
combined.
B A C K G R O U N D
Chronic pain of moderate or severe intensity and lasting six
months or longer affects around 20% of adults and imposes sig-
nificant reduction in quality of life (Moore 2013). Opioids have
long been used in the treatment of acute and cancer pain, and over
the last two decades there has been a marked increase in their pre-
scription for chronic non-cancer pain (CNCP), especially in the
USA, Australia, and Europe. Estimates of the numbers of people
with CNCP treated with opioids are not commonly available, but
one estimate for the UK indicates that almost one million people
may use some form of opioid (Gallagher 2009).
Several randomised controlled trials suggested that opioids pro-
vide modest pain relief in the short to medium term (typical trial
duration is 12 weeks; Furlan 2006; Kalso 2004). However, there
is much less evidence that opioids provide long-term pain relief
in CNCP (ASIPP 2012; Noble 2010), especially when statistical
imputation methods are used in which withdrawal for any reason
is regarded as treatment failure (and relevant to clinical practice),
in comparison to the common practice of carrying forward the
last observed pain readings to the end of the trial and using that
measurement to estimate efficacy (Moore 2012; Steiner 2011).
Adverse events, principally sedation, impaired cognitive function,
depression, constipation, and bladder dysfunction, are also com-
mon during opioid therapy (Benyamin 2008), with up to 80%
of users suffering at least one adverse event (Moore 2005). Long-
term opioid use can be associated with immune system depres-
sion, hormonal disturbances, and hyperalgesia (Benyamin 2008),
as well as fractures (Miller 2011), and increased all-cause mortality
in older people compared with other analgesics (Solomon 2010).
Opioid use also carries risks of tolerance, dependence, and abuse.
Practicalities of the real world like prescribing restrictions for non-
opioid analgesics, or guidelines that suggest early use of opioids,
can mean that many people are prescribed opioid drugs, some-
times inappropriately. The American Society of Interventional
Pain Physicians suggests that the majority of patients who start
chronic opioid treatment continue with the treatment throughout
their life (ASIPP 2012). On occasion, opioid doses are increased
as a result of insufficient analgesia or the development of tolerance
(i.e. requiring a higher dose to obtain the same therapeutic ben-
efit). This can lead to people being prescribed very high doses of
opioids, but still without acceptable pain relief. American opioid
sales quadrupled between 1999 and 2010 (ASIPP 2012). In the
USA, increased prescribing is associated with higher rates of over-
dose and overdose death (Paulozzi 2011), but with an indication
that 60% of CNCP opioid deaths occurred while opioids were
used as directed (ASIPP 2012). However, there is some evidence
to suggest that whilst the prescription of opioids remains high, it
decreased between 2012 and 2015 in the USA (Guy 2017).
A number of professional societies worldwide have produced guid-
ance advocating/promoting the judicious and careful use of opi-
oids. TheAmericanAcademyof PainMedicine, theAmericanPain
Society, and the American Society of Addiction Medicine jointly
advise that healthcare providers should exercise caution when pre-
scribing opioids, assessing circumstances and suitability on an in-
dividual basis (Chou 2009). Guidance in Washington State, USA
(Washington State Agency Medical Group 2010) has passed into
law (HB2876 2010). Current UK guidance is typical in that it
recognises that prescription opioids can lead to problem use, and
that there is considerable uncertainty in the literature about any
long-term benefits of continued use.
There is growing concern that the widespread use of opioids has
public health implications (Stannard 2012). The balance between
benefit and risks generated during long-term therapy with opioids
suggests that it may be neither clinically effective nor in patients’
best interests to continue opioid prescription without adequate
pain relief. There is, therefore, a potential need to facilitate and
maintain opioid dose reduction. For many patients it is likely
that long-term opioid treatment is continued even when benefit
is not demonstrated, and greater patient benefits may accrue from
opioid withdrawal. Patients who do not benefit from treatment in
terms of pain, or who suffer unacceptable adverse events, should
be helped to cease opioid treatment whilst concurrently addressing
their pain (Ballantyne 2003).
There is a growing recognition thatmany patients will reach a state
where the reduction of prescribed opioids is the desired and shared
goal of both patient and clinician. This state is sometimes reached
after a history of long-term, high-dose opioid use, making simple
unsupervised cessation clinically challenging, if not impossible.
Thismay occur, at least in part, because of the reluctance of patient
and prescriber to reduce the opioid dose for fear of worsening
pain, as well as issues of dependence and subsequent withdrawal
symptoms.
There are many studies of methods of withdrawal from opioids;
most, however, are undertaken in the context of addiction ser-
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vices for people with an opioid abuse problem. Our interest here
was in the planned reduction or total withdrawal of opioids pre-
scribed for pain management. Common opioid reduction tech-
niques in the addiction field are instructive and include opioid
replacement stabilisation and dose tapering, and may involve psy-
chological treatments (Amato 2011). Inducing withdrawal under
sedation using opioid antagonists such as naloxone, naltrexone,
or nalmefene is possible (Gowing 2009; Gowing 2010) but is not
recommended owing to unacceptable risks of adverse events. It is
unclear whether similar interventions are effective when adjusted
to CNCP in which treatment aims differ, or if other approaches
are more appropriate.
Description of the condition
Patients
• with chronic pain of a non-cancer-related origin (such as
neuropathic, musculoskeletal, visceral, or head pain)
• who are prescribed opioid medication for pain management
• who have a treatment goal of dose reduction or cessation of
opioid medicine
Description of the intervention
The interventions included any clinical method that aimed to fa-
cilitate opioid withdrawal or dose reduction as a compulsory or
optional aspect of treatment, as either a primary or a secondary
outcome. The intervention could be pharmacological, physiolog-
ical, psychological, or another, as long as its methods are docu-
mented clearly within the study.
How the intervention might work
Different methods will have different mechanisms. In particular,
we expect non-pharmacological treatment aimed at opioid reduc-
tion to operate principally through behaviour change, and phar-
macological methods to operate principally by reducing or man-
aging the adverse events of opioid use or opioid withdrawal.
Why it is important to do this review
Increased prescribing of opioids is a problem because of their po-
tential to cause harm, along with issues of limited relief and tol-
erance. Given the known risks of opioid therapy, it is appropriate
to continue to prescribe opioid medicines only to those people for
whom the treatment produces acceptable benefits, weighed against
any adverse events. Given evidence in many societies of huge in-
creases in the use of medicinal opioids for CNCP, their limited
effectiveness, and their adverse event profile, we can reasonably
expect a large increase in people seeking clinical help to reduce
or halt opioid consumption. An evidence summary of the most
effective methods is needed, along with guidance on treatment
development.
O B J E C T I V E S
To investigate the effectiveness of different methods designed to
achieve reduction or cessation of prescribed opioid use for the
management of chronic non-cancer pain in adults compared to
controls.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Included studies had to be randomised controlled trials (RCTs)
comparing opioid users receiving an intervention with a control
group receiving treatment as usual, active control, or placebo. The
aim of the study had to include a treatment goal of dose reduction
or cessation of opioid medicine.We excluded studies that included
fewer than 10 participants in each arm at post-treatment.
Types of participants
Participants were adults (18 years of age or older) using prescrip-
tion opioids for management of CNCP with a duration of at least
three months. Pain conditions could include but were not lim-
ited to: neuropathic pain, myofacial pain, back pain, fibromyalgia,
headache, abdominal, neck or musculoskeletal pain.
We excluded studies involving only participants with issues of
addiction, abuse, dependence, or non-prescribed opioid use, and
involving participants using opioids for pain relief during palliative
care. This is because the aims of treatment for these populations
differ substantially from those for the population of interest.
Types of interventions
We planned to include in this review a large variety of interven-
tion types. Interventions could be based in pharmacology, physi-
ology, psychology, spirituality, or another approach, provided that
the underpinning methodology was well documented in the study
and was valid. Eligible intervention types could include opioid
antagonist treatment, dose tapering, or opioid replacement with
other pain-relieving medication. Interventions could also involve
physical therapy, massage, disability management, complemen-
tary therapies, or psychological approaches such as cognitive be-
havioural therapy, counselling, and coping techniques.
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We excluded studies encompassing only interventions specifically
for opioid addiction, medication overuse, dependence, or with-
drawal symptoms.
Types of outcome measures
We extracted relevant outcomes before treatment, immediately
after treatment, and at follow-up, at least three months later but
no longer than a year. If there were two follow-up time points, the
later would be chosen.Where appropriate, we extractedmeans and
standard deviations of outcomes assessed with psychometrically
tested measures.
Primary outcomes
The primary outcomes of this review are:
• prescribed opioid use in adults;
• adverse events related to opioid reduction.
Secondary outcomes
Secondary outcomes are:
• pain intensity/severity;
• psychological functioning;
• physical functioning.
Search methods for identification of studies
Electronic searches
We have conducted two searches to date. For the original review
we searched the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, and Embase from 1999 to April 2013.
For this update we searched the same databases on 4 January 2017
to identify any further studies meeting the inclusion criteria:
• CENTRAL (via CRSO) - April 2013 to 4/1/17;
• MEDLINE (via OVID) - April 2013 to December week 1
2016;
• Embase (via OVID) - April 2013 to 2017 week 1.
We did not restrict the searches based on language. See Appendix
1 for search strategies.
Searching other resources
We searched the reference lists of retrieved papers and carried out a
citation search to identify any potentially eligible papers not found
through the electronic search. We also contacted the authors of
studies identified for inclusion to obtain additional data relevant to
this review and not included in the published articles. Finally, we
searched Clinicaltrials.gov for additional trials that met eligibility.
Data collection and analysis
Selection of studies
We filtered search results initially by title and abstract, and ob-
tained full copies of potentially eligible studies. Two review au-
thors read the studies to confirm eligibility, with disagreements
discussed and mediated by a third review author if necessary. In
the first version of this review, we limited the selection of studies to
those published from 2000 onwards, to reflect the major growth
in opioid prescribing for CNCP after 2000.
Data extraction and management
Two review authors extracted data using a standard data extraction
form to include details of participants, intervention method and
duration, quantity and type of opioid used, study design, and
treatment outcomes. We discussed any discrepancies with a third
review author.
Assessment of risk of bias in included studies
We assessed risk of bias in the included studies using the Cochrane
’Risk of bias’ tool (Higgins 2011) to assign judgements of high,
low, or unclear risk of bias to sequence generation, allocation con-
cealment, blinding, incomplete outcome data, selective reporting,
and any other potential sources of bias in the included studies.
Specifically for other sources of biases, we assessed the sample size
as a risk of bias and coded any studies that included fewer than
100 participants as high risk of bias. Two authors (CE, EF) in-
dependently assessed risk of bias for each study and resolved dis-
agreement by discussion. ’Risk of bias’ assessments are included in
the Characteristics of included studies.
We assessed the following for each study.
• Random sequence generation (checking for possible
selection bias). We assessed the method used to generate the
allocation sequence as: low risk of bias (any truly random
process, e.g. random number table; computer random number
generator); unclear risk of bias (method used to generate
sequence not clearly stated); and high risk of bias (studies that
included a biased randomisation procedure). We excluded
studies that were not randomised.
• Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during recruitment,
or changed after assignment. We assessed the methods as: low
risk of bias (e.g. telephone or central randomisation;
consecutively numbered, sealed, opaque envelopes); unclear risk
of bias (method not clearly stated).
• Blinding of outcome assessment (checking for possible
detection bias). We assessed the methods used to blind outcome
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assessors from knowledge of which intervention a participant
received. We assessed the methods as: low risk of bias (study had
a clear statement that outcome assessors were unaware of
treatment allocation, and ideally described how this was
achieved); unclear risk of bias (study stated that outcome
assessors were blind to treatment allocation but lacked a clear
statement on how it was achieved).
• Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data). We assessed the methods used to deal with
incomplete data as: low risk (attrition fully reported and no
differences between completers and non-completers); unclear
risk of bias (attrition unclear or unclear differences between
completers and non-completers); high risk of bias (attrition not
reported or differences between completers and non-completers).
• Selective reporting (checking for reporting bias). We
assessed whether all outcomes were reported in the paper as low
risk of bias. High risk of bias would be given when data were not
reported and not provided on request.
• Size of study (checking for possible biases confounded by
small size). We assessed studies as being at low risk of bias (200
or more participants per treatment arm); unclear risk of bias (50
to 199 participants per treatment arm); high risk of bias (fewer
than 50 participants per treatment arm).
Measures of treatment effect
We planned to use risk ratio (RR) to establish statistical difference,
and number needed to treat for an additional beneficial outcome
(NNTB) and number needed to treat for an additional harmful
outcome (NNTH) as absolute measures of benefit or harm.
We defined a ’responder’ to treatment as a participant who experi-
enced at least a 50% reduction in opioid consumption, or achieved
complete opioid withdrawal or a reduction of their intake to below
’high’ dose, which we identified as 120 mg a day oral morphine
equivalent. Trials have previously shown that dose-related harms
of taking more than 120 mg a day of opioid drugs outweigh the
benefits (Braden 2010; Morasco 2010; Sullivan 2010), and pub-
lished guidelines, including those of the American Pain Society
and the American Academy of Pain Medicine (Chou 2009), and
by the Washington State Agency Medical Group 2010, recom-
mend a cut-off at 120 mg a day. A responder also had to have,
at worst, no increase in pain as a result of the intervention. Both
aspects of improvement had to be maintained for at least three
months post intervention.
Our planned analyses included:
• Treatment versus control opioid reduction (post-treatment);
• Treatment versus control opioid reduction (follow-up);
• Treatment versus control pain intensity (post-treatment);
• Treatment versus control pain intensity (follow-up);
• Treatment versus control psychological functioning (post-
treatment);
• Treatment versus control psychological functioning (follow-
up);
• Treatment versus control physical functioning (post-
treatment);
• Treatment versus control physical functioning (follow-up).
We planned to describe adverse events reported in all studies.
Unit of analysis issues
The unit of analysis was the individual participant.
Dealing with missing data
Weused the intention-to-treat approach to deal withmissing data.
We would include in the analysis all participants who were ran-
domised to treatment, and we assumed that those for whom fol-
low-up data were not available were non-responders.
Assessment of heterogeneity
We anticipated that there would be significant clinical heterogene-
ity between studies (participants, conditions, interventions), so we
planned to pool data using a random-effects model.
Assessment of reporting biases
We planned to assess publication bias by estimating the number of
unpublished null studies needed to make a clinical finding likely
to be unstable or irrelevant (Moore 2008). Unfortunately, this was
not possible because we were not able to calculate any effect sizes.
Data synthesis
We planned to combine data using Review Manager 5 (RevMan
5) (RevMan 2014).We planned to include dichotomous outcome
analysis for the number of people who achieved a 50% reduc-
tion in opioid consumption. For this analysis, we planned to use
Mantel-Haenszel statistics, and report risk ratio outcomes. We de-
scribed any adverse events in the trials. For our secondary out-
comes, we planned to analyse pain intensity, psychological func-
tioning, and physical functioning in separate analyses using in-
verse variance methods in a random-effects model. We planned to
summarise heterogeneity using I2 statistics (Higgins 2003), which
we planned to interpret following Deeks 2011 reference points of
0% to 40%: might not be important; 30% to 60%: may represent
moderate heterogeneity; 50% to 90%: may represent substantial
heterogeneity; 75% to 100%: considerable heterogeneity.
If data were homogeneous we planned to combine data in a meta-
analysis, and if heterogeneous to describe the findings from the
studies separately, focusing on our primary and secondary out-
comes.
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Quality of the evidence
We planned that two review authors (CE, EF) would indepen-
dently rate the quality of the outcomes. We planned to use the
GRADE approach to rank the quality of the evidence using
RevMan 5 (RevMan 2014), and the guidelines provided in chap-
ter 12 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Schünemann 2011).
TheGRADE approach uses five considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of the body of evidence for each outcome.
The GRADE system uses the following criteria for assigning grade
of evidence.
• High: we are very confident that the true effect lies close to
that of the estimate of the effect;
• Moderate: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of
effect, but there is a possibility that it is substantially different;
• Low: our confidence in the effect estimate is limited; the
true effect may be substantially different from the estimate of the
effect;
• Very low: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
We planned to decrease our rating by one (-1) or two (-2) if we
identified:
• serious (-1) or very serious (-2) limitation to study quality;
• important inconsistency (-1);
• some (-1) or major (-2) uncertainty about directness;
• imprecise or sparse data (-1);
• high probability of reporting bias (-1).
’Summary of findings’ table
We planned to include a ’Summary of findings’ table to present
the main findings for comparison of interventions to reduce opi-
oid consumption versus control in a transparent and simple tab-
ular format. In particular, we planned to include key information
concerning the quality of evidence, the magnitude of effect of the
interventions examined, and the sum of available data on the out-
comes of reduction of opioid consumption, adverse events, pain
intensity, psychological functioning, and physical functioning.We
plan to include a ’Summary of findings’ table in the next update,
providing sufficient evidence is available.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses to assess the effect of entry dose
on intervention efficacy, and to compare outcomes between pain
conditions or intervention type if sufficient data were available.
Sensitivity analysis
We planned to perform a sensitivity analysis should we suspect
that studies with high risk of bias were significantly skewing results
of a comparison, removing studies from the analysis to assess their
influence.
R E S U L T S
Description of studies
Results of the search
This is an updated search of a review previously published in 2013
(Windmill 2013). During the first search of databases from 1999
to April 2013, we included three papers that reported on two
studies (Naylor 2010; Zheng 2008). We searched CENTRAL,
MEDLINE and Embase for studies eligible for inclusion. In the
second search fromApril 2013 to January 2017 we identified 3480
abstracts; 2878 abstracts after duplicates were removed (Figure 1).
We identified two new studies that met eligibility for this update
(Garland 2014; Sullivan 2017). We contacted all first authors of
the included studies for additional studies thatwe hadnot captured
in our search, and identified one further study that met eligibility
(Jamison 2010). Therefore, three studies are new to this update
(Garland 2014; Jamison 2010; Sullivan 2017), resulting in five
studies overall.
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Figure 1. Study flow diagram
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Included studies
Five studies met the inclusion criteria (Garland 2014; Jamison
2010; Naylor 2010; Sullivan 2017; Zheng 2008) that included
278 participants with chronic pain (women = 184; men = 94;
mean age = 49.63 years, SD = 11.74). Three studies included par-
ticipants with mixed chronic pain conditions, Naylor 2010 ex-
clusively included participants with chronic musculoskeletal pain,
and participants in Jamison 2010 reported chronic neck or back
pain. Jamison 2010;Naylor 2010, Sullivan 2017, and Zheng 2008
reported that the average pain duration was 12.68 years (SD =
10.72).
Of the five studies, two studies aimed to reduce opioid consump-
tion via cognitive behavioural therapy (CBT) (Sullivan 2017) or
electroacupuncture (Zheng 2008). Two studies aimed to reduce
opioidmisuse in people with chronic pain (Garland 2014; Jamison
2010). These studies delivered CBT or mindfulness treatments to
the participants. One study aimed to increase treatment compli-
ance and adherence in people with chronic pain receiving a pain-
management treatment (Naylor 2010 ). Here, the authors deliv-
ered CBT to everyone, and then provided a therapeutic interactive
voice response to participants randomised to the treatment condi-
tion to improve maintenance of treatment. Two studies compared
treatment to active controls and the remaining studies used stan-
dard care controls. Full details can be found in the Characteristics
of included studies table.
In addition to published data, two author groups (Naylor 2010;
Zheng 2008) provided additional data for the outcomes of pain
and psychological functioning (Appendix 2). The remaining stud-
ies included data pertinent to this review meaning that we did not
need to contact them for additional data.
Excluded studies
We excluded seven studies from this review, none new to this up-
date. Three did not meet methodological standards (Crisostomo
2008; Krymchantowski 2003; Townsend 2008), while four did
not have opioid reduction as a primary aim (Hale 2007; Potter
2010; Roland 2011; Weinstein 2006). Full details are available in
the Characteristics of excluded studies table.
Risk of bias in included studies
We assessed risk of bias using the Cochrane ’Risk of bias’ tool
(Higgins 2011). Justification for judgements can be found in
Characteristics of included studies and the figures of bias assess-
ments in Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Allocation
Random sequence generation
Three studies described sound randomisation procedures and we
judged them to be low risk of bias, one study did not give a clear
description, and we judged one study to have a high risk of bias
as it randomised people based on the order that they were entered
into the trial.
Allocation concealment
Three studies provided adequate descriptions of allocation con-
cealment and we gave a low risk of bias rating, whilst two studies
did not describe methods to conceal allocation and we marked
them as unclear risk.
Blinding
Detection bias
We rated one study as low risk of bias for blinding outcome asses-
sors, and the remaining four studies as unclear risk.
Performance bias
We excluded performance bias from this review as it is not possible
to blind personnel who are delivering psychological treatments, or
participants who are receiving them.
Incomplete outcome data
For attrition bias, one study did not have any dropouts and was
marked as low risk of bias. The four further studies were judged
to be unclear because they did not note differences between com-
pleters and non-completers.
Selective reporting
Most studies reported data for all outcomes and were marked as
low risk of bias. However, one study had missing data and was
rated as high risk of bias.
Other potential sources of bias
We rated all studies as high risk of bias for including small sample
sizes (fewer than 50 participants per treatment arm).
Effects of interventions
All studies provided data to be analysed. However, due to the het-
erogeneity of the studies, we did not pool data in a meta-analy-
sis. Therefore, we did not conduct GRADE analyses. We describe
findings from each study.
Primary Outcomes
Opioid use
Garland 2014 compared a Mindfulness-Oriented Recovery En-
hancement (MORE) treatment with a support group control.
They did not assess objective opioid use before or after the trial.
However, desire for opioids and opioid misuse was reported. Au-
thors reported that the MORE group had a significantly lower
desire for opioid consumption post treatment, but results were
not maintained at follow-up. TheMORE group also self-reported
significantly lower opioid misuse (63%) compared to the support
group (32%) at post-treatment. However, similar to the desire for
opioids, participants did not differ at follow-up.
Jamison 2010 did not assess objective opioid use before or after
the trial. A self-reported, prescription drug-use questionnaire was
taken, but differences between groups at post-treatment were not
reported.
Naylor 2010 compared Therapeutic Interactive Voice Response
(TIVR) through a computer for four months with usual treat-
ment, following CBT delivered to all participants for 11 weeks.
The TIVR group (n = 26, 14 of whom were using opioids at base-
line) reported a significant decrease in opioid use from baseline
at both four- and eight-month follow-ups, with three participants
stopping opioid use entirely. The standard care control (n = 25,
15 of whom were using opioids at baseline) significantly increased
opioid consumption from baseline to the eight-month follow-up,
and threemore participants began opioid treatment. At post-treat-
ment and eight-month follow-up, the difference in mean opioid
dose was significant, with the TIVR group using less than the
standard care control.
Sullivan 2017 randomised 35 participants to an opioid-tapering
support intervention (n = 18) or usual care (n = 17). Both the
treatment and control group reduced their intake of opioids at
22 weeks, and there was no significant difference between groups
(morphine-equivalent doses (MED) taper support = 111.94, SD
= 153.63; usual care = 169.85, SD = 201.31). Similarly at follow-
up, no between-group differences were identified (MED) taper
support = 99.51, SD = 151.99; usual care = 138.24, SD = 155.85).
There was also no significant difference in the percent reduction
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frombaseline and 22weeks or 34weeks for either group.However,
opioid consumption was reduced compared to baseline levels.
Zheng 2008 randomised participants to receive either real elec-
troacupuncture (REA; n = 17) or sham electroacupuncture (SEA;
n = 18) for 20 minutes twice a week for six weeks. Opioid con-
sumption varied considerably within each group, and the mean
consumption at baseline differed between groups, being 462 (±
463) mg a week in the REA group and 296 (± 288) mg a week
in the SEA group. Participants in both groups who completed the
six weeks of treatment (REA = 12; SEA = 14) reported a signifi-
cant reduction in opioid consumption between baseline and the
end of treatment at eight weeks, of 64% and 46% in the REA
and SEA groups, respectively. In an intention-to-treat analysis, the
reductions were 39% and 26%. The difference between groups
was not statistically significant. At follow-up at 20 weeks (REA =
9; SEA = 14), opioid consumption had gradually increased in the
REA group and was significantly higher at 20 weeks than at eight
weeks, while in the SEA group there was no significant change.
Adverse events
Garland 2014 did not report the occurrence of adverse events.
When we contacted the study authors, they reported that there
had been no adverse events.
Jamison 2010 reported adverse events across all participants of dry
mouth (44.9%), constipation (38.4%) sweating (37.5%),memory
lapse (28.4%), weakness (24.1%), itching (23.9%), and headaches
(28.4%). The treatment group reported lower rates of constipa-
tion and itching, but higher vision problems. The control group
reported more severe constipation, sneezing, and nightmares than
the treatment group.
Naylor 2010 did not report on adverse events, but contact with
the study authors confirmed that there were no adverse events
associated with treatment.
Sullivan 2017 reported one severe study-related adverse event in
the taper-support group. The study psychiatrist prescribed nor-
triptyline during the participant’s initial psychiatric evaluation,
which the participant had a severe reaction to. This medication
was discontinued and symptoms resolved.
Zheng 2008 reported a total of 33 adverse events during the treat-
ment period with REA, and 19 with SEA, none of which were
classed as serious adverse events. Opioid-based adverse events de-
creased from baseline to eight weeks after treatment by 40% in
the REA group and 45% in the SEA group.
Secondary Outcomes
Pain intensity
These numbers are from data supplied by the study authors (
Appendix 2) and differ slightly from the published data.
Garland 2014 used the Brief Pain Inventory, pain intensity sub-
scale and found that theMORE group reported significantly lower
pain intensity at post-treatment (Mean (M) = 4.86, SD = 1.38)
that met the threshold for minimally clinically significant change,
in comparison to the support group (SG) control group (M =
5.71, SD = 1.58). This between-group difference was maintained
at follow-up (MORE M = 4.77, SD = 1.95; SG M = 6.10, SD =
1.48).
Jamison 2010 assessed pain using the Brief Pain Inventory, pain
intensity subscale. However, post-treatment means and standard
deviations were not reported.
Naylor 2010 analysed pain using the McGill Pain Questionnaire,
reported inNaylor 2008 (Naylor 2010). TheTIVRgroup reported
a decrease in typical pain from baseline to eight months from 5.7/
10 to 3.4/10, and the standard care control from 6.8 to 5.7. The
difference between groups was statistically significant.
Sullivan 2017 assessed pain intensity using the Brief Pain Inven-
tory, pain severity subscale. There was no significant difference
between groups at 22 weeks (taper support = 4.72 , SD = 1.62;
usual care = 5.77, SD = 1.92) or at 34 weeks (taper support = 4.67
, SD = 1.79; usual care = 6.16, SD = 2.64).
Zheng2008 used theVisual Analogue Scale to assess pain intensity.
Average pain at baseline was 4.9/10 in the experimental group
and 5.6/10 in the control group, and post-treatment scores were
4.2 and 5.4, respectively. No differences were detected between
groups. At 20 weeks average pain scores were 3.6 and 4.6.
Psychological function
Garland 2014 assessed depression using the Calgary Symptoms
of Stress Inventory, depression subscale. There were no between-
group differences at post-treatment (MORE = 8.20, SD = 7.09;
SG = 10.76, SD = 6.44). Depression was not assessed at follow-
up.
Jamison 2010 reported that the control group had significantly
higher scores compared to the treatment group on anxiety and
depression measures (treatment = 6.06, SD = 3.55; standard care
= 9.00, SD = 3.39; treatment = 8.1, SD = 4.8; standard care =
9.06, SD = 4.11) respectively.
Naylor 2010 reported a decrease in scores of depression through-
out the study, using the Beck Depression Inventory. There were
significant between-group differences, favouring lower scores in
the experimental group compared to the control group at post-
treatment (TIVR = 10.4, SD = 6.4; standard care = 16.7, SD =
11.2) and eight-month follow-up (TIVR = 8.1, SD = 4.8; stan-
dard care = 14.9, SD = 8.7).
Sullivan 2017 assessed depression using the Patient Health Ques-
tionnaire-9. There were no significant group differences at 22
weeks (taper support = 8.88, SD = 7.49; usual care = 11.27, SD =
6.58), or at 34 weeks (taper support = 9.00, SD = 5.80; usual care
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= 11.13, SD = 7.53).
Zheng 2008 reported a significant decrease in depression scores
(Beck Depression Inventory) from baseline to post-treatment at
eight weeks in the REA group, from 18 to 17. Scores in the SEA
group also decreased, from 19 to 15. At final measurement at 20
weeks, the REA group mean score was 14, and the SEA group
mean score was 15. There was no significant difference between
the groups at either time point.
Physical function
Garland 2014 assessed functional interference with the Brief Pain
Inventory. The MORE group reported a significantly lower pain-
related functional interference compared to the SG at post-treat-
ment (MORE M = 5.22 SD = 1.88; SG M = 6.90, SD = 1.50),
and the between-groups difference was maintained at follow-up
(MORE M = 4.60 SD = 2.66; SG M = 6.75, SD = 1.86).
Jamison 2010 reported that there were no differences between
treatment and control at six-month post-treatment on the Pain
Disability Index.
Naylor 2010 reported physical function using the SF-36 Physi-
cal Function composite scale. The experimental group showed a
small increase (from 31/100 to 40/100) in functioning over eight
months, while the control group did not (29/100 to 31/100). The
difference between groups was statistically significant.
Sullivan 2017 assessed functional interference with the Brief Pain
Inventory, interference subscale. Significant groupdifferenceswere
identified at 22 weeks (taper support = 4.55 , SD = 2.39; usual
care = 6.38, SD = 2.11). There were also group differences at 34
weeks, but these were only trending in favour of the taper support
group (taper support = 4.49 , SD = 2.08; usual care = 6.05, SD =
2.72).
Zheng 2008 did not measure physical function.
D I S C U S S I O N
Summary of main results
We included three new studies in this update. However, there
remain no adequate data fromwhich to draw any conclusions from
five small studies with different interventions and only 278 treated
participants. Therefore, our conclusions for this review have not
changed.
Overall completeness and applicability of
evidence
Because of the very small number of included studies, for the
previous version of the review we decided to additionally investi-
gate methods of prescription opioid reduction that were not ran-
domised controlled trials, in case this was a more commonly used
study design. In 2013, we looked at papers from the previous
search results and additional reference searching. Inclusion criteria
remained the same as in the main search, excepting the criteria
of randomised controlled design. The overall completeness and
applicability from the previous update are still relevant for this
update, due to the lack of evidence in this area and the complexity
of designing and conducting an RCT to investigate this problem.
In contrast to the randomised evidence, there was a much larger
body of evidence from observational studies. A three-week, outpa-
tient, intensive, multidisciplinary pain rehabilitation programme
conducted at theMayo Clinic Pain Rehabilitation Center demon-
strated large reductions in medication use, particularly in use of
opioids, in a number of publications in recent years. The three-
week programme included stretching, goal setting, stress manage-
ment, physical therapy, pain management, relaxation, and occu-
pational therapy (Mayo 2017). Typical opioid use in patients at
admission was high, often above 40% and as high as 100%, and at
discharge and follow-up was low, often below 10%. The analyses
were retrospective or longitudinal, and not randomised, but rep-
resented an interesting body of additional data. Results like these
were obtained for 159 patients with fibromyalgia (Hooten 2007),
for 383 patients after fusion or non-fusion spinal surgery, or no
surgery (Crisostomo 2008), in a group of 411 patients with a wide
range of age and non-cancer pain conditions (Darchuk 2010), and
for 634 chronic pain patients of different smoking status (Hooten
2009). In a group of 213 patients all taking opioids on admission,
the rate of opioid use at discharge was 7% and remained low for
as long as six months after admission (Townsend 2008).
Change in medication use, including opioid medication use, is
a common feature of multimodal and multi-component pro-
grammes of cognitive behavioural therapy for chronic pain. The
evidence for such programmes in improving disability status and
reducing the impact of mental health outcomes is promising
(Williams 2012). At present, however, it is not possible to extract
and describe the components of such programmes for their effec-
tiveness on medication consumption outcomes, although individ-
ual trials report positive effects. A challenge will be to determine
methods of analysis, if possible, of such treatment packages with
multiple components addressing multiple outcomes.
Others have sought evidence from literature reviews to prevent
opioid over-use, and have put forward what is claimed to be an
evidence-based algorithmic approach (Atluri 2012).
Legislation (HB2876 2010) has had a major effect on opioid pre-
scribing in Washington State, where a de-facto limit of 120 mg
oral morphine equivalent a day is suggested, with higher doses
available after consultationwith a specialist. An interim assessment
showed that about half of physicians followed guidance on opioid
prescribing, and that about 90% of them found it useful (DLI
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2009). A survey has shown large falls in opioid prescribing (27%),
and in the proportion taking more than 120 mg a day oral mor-
phine equivalents (35%), as well as in opioid-related deaths (50%)
(Franklin 2012). The benefits of treating patients with chronic
pain continue to show a lack of long-term benefit. A systematic
review assessing opioid consumption comparing to placebo or no
opioids did not find studies assessing long-term follow-up (i.e. one
year). Opioids were found to be frequently abused and misused in
chronic pain samples, and associated with dependence, fractures,
and myocardiac infarctions (Chou 2015). Further, recent recom-
mendations from the Centres for Disease Control state that opi-
oid therapy should not be given to people with chronic pain (not
associated with a life-limiting condition) due to potential harm
and lack of medium- and long-term benefit (Dowell 2016).
Quality of the evidence
The evidence base identified by this review is small and limited and
we were unable to perform a GRADE assessment of the certainty
of evidence in this area. The individual studies have small numbers
of participants, and overall we have evidence of the experience
of only 278 chronic pain patients. There is a heterogeneity of
interventions and outcome reporting. Poor reporting is common,
meaning that the risk of bias was often unclear or high.
Potential biases in the review process
We were not aware of any biases in the review process, although
there was a potential for bias in searching for studies. While the
intention to reduce opioid use may have been clear, possible in-
terventions may have been disparate.
Agreements and disagreements with other
studies or reviews
We found no other similar reviews.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There were too few data in this review to permit any comments
about implications for practice.
Implications for research
General implications
There is an urgent need for more research. There is a growing
population of people with chronic pain, who also have chronic use
of opioids, which are thought to be untherapeutic and for whom
reduction is a primary clinical goal. We are unable to reduce our
uncertainty around any treatment offered to these people for this
purpose.
Design
We need more randomised controlled trials of theoretically
grounded behaviour-change interventions that focus on opioid
medication use in the context of medically treated chronic pain.
There should be no fewer than 100 participants in each trial arm.
Measurement (endpoints)
More work is needed to agree the best endpoints for treatments
of medication reduction. Measures of the type of opioid and the
median daily opioid dose in morphine equivalents consumed in a
particular time period are critical to report. In addition, measures
of patient-relevant outcomes such as mood, social functioning,
and personal role functioning are also important to assess.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Garland 2014
Methods Randomised, 8-week, active-control RCT
Assessments at pre-post treatment and 3-month follow-up
Participants Chronic pain condition: mixed (including fibromyalgia, arthritis, cervicalgia, lumbago,
and other)
115 participants were randomised, MORE (n = 57), support group (n = 58)
Female 78; male 37
Mean age = 48 years, SD = 13 years
Interventions Mindfulness-oriented recovery enhancement (MORE): delivered to participants in
8 two-h sessions by a Master’s level clinical social worker with > 10 years of clinical
experience. 15-min homework sessions were given to be practiced daily
Support group: 8 two-h sessions for participants to discuss topics pertinent to chronic
pain and long-term opioid use were discussed. Topics were designed to match sessions
in the MORE group. Lead by a Master’s level clinical social worker
Outcomes Prescribed medication use: no measure of prescription. Measures of desire for opioids
and Current Opioid Misuse Measure were included
Pain: BPI, pain severity subscale
Psychological function: CSQ; Calgary Symptoms of Stress Inventory
Physical function: BPI, pain interference subscale
Notes Funded by National Institute on Drug Abuse and a grant from Fahs-Beck Fund for
Research and Experimentalation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were randomly allocated to
MORE or to the SG. Order of randomisa-
tion was computer generate via simple ran-
domisation blocks of varying sizes (6-8) to
preserve unpredictability of allocation.”
Allocation concealment (selection bias) Low risk “Order of randomisation was computer
generated via simple randomisation blocks
of varying sizes (6-8) to preserve unpre-
dictability of allocation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Assessments were conducted by project
staff blind to each respondent’s group as-
signment, which was concealed through-
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Garland 2014 (Continued)
out the study”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition is described but analyses of dif-
ferences between completers andnon-com-
pleters was not conducted
Selective reporting (reporting bias) Low risk Comprehensive reporting of outcomes
Size High risk 42/46 received at least 1 session
Jamison 2010
Methods Randomised trial, standard medical care control
Assessments at baseline and 6 months
Participants Chronic pain patients with a history or risk of opioid misuse. All participants had chronic
back or neck pain
42 patients were randomised; CBT (n = 21), standard medical care (n = 21)
Female 20; male 22
Mean age = 46.79 years, SD = 7.27 years
Interventions CBT for prevention of opioid misuse: group and individual sessions were delivered
to participants. Treatment was composed of 5 components; electronic monthly di-
aries, monthly urine screens, monthly completion of the Opioid Compliance Checklist,
monthly group education sessions and worksheets, individual motivational compliance
counselling. Groups and individual sessions included enhancing and maintaining mo-
tivation to avoid illicit substance use, coping with urges, problem solving, and lifestyle
balance. Participants were provided with discussions round risk factors, motivational
counselling, homework, and completed a monthly opioid compliance checklist. Treat-
ment lasted 6 months
Standard medical care: no description provided
Outcomes Prescribed medication use: no measure of prescription. Measures of desire for opioids
and Current Opioid Misuse Measure were included
Pain: BPI, pain severity subscale
Psychological function: HADS
Physical function: BPI, pain interference subscale, Pain Disability Index
Notes The study was supported in part by an investigator-initiated grant fromEnd Pharmaceu-
ticals, Chadds Ford, PA and Grants R21 DA024298, Jamison PI and K23DA020682
Wasan PI from theNational Institute onDrugAbuse of theNational Institutes ofHealth,
Bethesda, MD, and the ARthritis Foundindation (Wasan)
Risk of bias
Bias Authors’ judgement Support for judgement
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Jamison 2010 (Continued)
Random sequence generation (selection
bias)
High risk “...assignment to treatment group based on
a randomized number list created before
the start of the study. Subjectswere assigned
to their group in the order that they entered
into the study”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No description provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition is described but analyses of dif-
ferences between completers andnon-com-
pleters was not conducted
Selective reporting (reporting bias) High risk Post-treatment means and SDs are not pro-
vided for all measures
Size High risk 21 per group
Naylor 2010
Methods 11 weeks plus 120 days’ duration, randomised, standard care, controlled trial. Assess-
ments at baseline, post intervention, 4 months, and 8 months post intervention
Participants Chronic pain condition: chronic musculoskeletal pain
55 participants randomised, 51 participants received allocated intervention
Female 44, male 7
Mean age 46 (SD ± 11.5) years
Interventions All participants received 11 90-min sessions of CBT pre-randomisation
Therapeutic Interactive Voice Response (n = 26)
Standard care (n = 25)
Outcomes Prescribed medication use: dose and frequency of opioid analgesics, non-steroidal anti-
inflammatory drugs, benzodiazepines, and antidepressants
Pain: Short Form MPQ, Pain Symptoms sub scale from the TOPS
Psychological function: BDI, SF-36 Mental Function Scale, CSQ
Physical function: SF-36 Physical Function Scale, TOPS Total Pain Experience Scale
Notes 4 participants were excluded following randomisation.
This research was supported by grants from the National Institute of Drug Addiction
(NIDA) R21 DA016115, National Institute of Arthritis, Musculoskeletal Diseases (NI-
AMS) R01 AR052131, and National Institute on Alcohol Abuse and Alcoholism (NI-
AAA) R01 AA014270
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Naylor 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized using a stratified block de-
sign”
Allocation concealment (selection bias) Low risk “consecutively numbered, sealed envelopes
were prepared for each gender group by the
statistician”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts during the study
Selective reporting (reporting bias) Low risk Comprehensive reporting of outcomes
Size High risk 25/26 per group
Sullivan 2017
Methods Non-blinded RCT. 18-week intervention. Assessments at baseline, 22 weeks, and 34
weeks
Participants Chronic pain condition: chronic non-cancer pain
35 participants randomised, 18 to taper support; 17 to usual care
Female 25, male 10
Mean age 54.4 years (SD = 10.1)
Interventions All participants were shown a 14-min video of patients who had successfully tapered off
opioids before randomisation
Opioid tapering group: participants underwent motivational interviewing and then
17 30-min weekly sessions with Physician Assistant delivering CBT and occasional mo-
tivational interviewing. Booster phone calls were scheduled at 24, 39, and 32 weeks.
Sessions were conducted in person and over the phone. Participants received workbooks
and CDs throughout treatment. Participants’ opioid medication was tapered 10% for
the first 3 weeks, then reassessed and reduced 10% for the following weeks. Participants
could pause tapering, but were not allowed to remain in the study if they increased opioid
prescription
Usual care: participants in the control group received usual care from physicians, with
no restrictions on medications during the study period
Outcomes Prescribed medication use: mean daily opioid dose
Pain:BPI, pain severity subscale
Psychological function: Patient Health Questionnaire-9 (depression)
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Sullivan 2017 (Continued)
Physical function: BPI, pain interference subscale
Notes This work was supported by Grant R34DA033384 from the National Institute on Drug
Abuse to Mark Sullivan
Dr. Sullivan reports consulting with Chrono Therapeutics. Other authors report no
conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Study participants were randomized 1:1
to receive either the opioid taper interven-
tion or usual care according to a computer-
generated randomisation list in sealed en-
velopes”
Allocation concealment (selection bias) Low risk “Study participants were randomized 1:1
to receive either the opioid taper interven-
tion or usual care according to a computer-
generated randomisation list in sealed en-
velopes”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition is described but analyses of dif-
ferences between completers andnon-com-
pleters was not conducted
Selective reporting (reporting bias) Low risk All outcomes reported
Size High risk 17/18 per treatment arm
Zheng 2008
Methods 20 weeks, randomised, single-blind, sham-controlled trial
Assessments at baseline and at weeks 5, 8, 12, 16, and 20
Participants 35 participants with non-malignant pain for > 3 months, using opioid medication
Female 17, male 18
Mean age 50 years (SD = 11 years)
Interventions Electroacupuncture (n = 17) for 20 min twice/week for 6 weeks
Sham electroacupuncture (n = 18) for 20 min twice/week for 6 weeks
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Zheng 2008 (Continued)
Outcomes Prescribed opioid use: dosage of opioid-like medications and adverse events (type and
frequency)
Pain: pain intensity visual analogue scale; MPQ
Psychological function: BDI
Physical function: none
SF-36 v2 Health Survey
Notes The study was supported by a research grant provided by the then Faculty of Life Sci-
ences, RMITUniversity. Ms. Jessica Guo, a research candidate, was supported by an Aus-
tralian Postgraduate Award (APA) and an Australian Acupuncture and ChineseMedicine
Association (AACMA) Research Grant 2005
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Block randomisation code was computer
generated and stored in a password pro-
tected computer”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Single blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition is described but analyses of dif-
ferences between completers andnon-com-
pleters was not conducted
Selective reporting (reporting bias) Low risk All data reported. Last observation carried
forward used for 9/35
Size High risk 17/18 per treatment arm
BDI: Beck Depression Inventory
BPI: Brief Pain Inventory
CBT: cognitive behavioural therapy
CSQ: Coping Strategies Questionnaire
HADS: Hospital Anxiety and Depression Scale
MPQ: McGIll Pain Questionnaire
RCT: randomised controlled trial
TOPS: Treatment Outcomes in Pain Survey
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Crisostomo 2008 Not randomised
Hale 2007 Primary aim of study was not opioid reduction
Krymchantowski 2003 < 10 participants in each arm at post-treatment
Potter 2010 Primary aim of study was not opioid reduction
Roland 2011 Primary aim of study was not opioid reduction
Townsend 2008 Not randomised
Weinstein 2006 Primary aim of study was not opioid reduction
Characteristics of ongoing studies [ordered by study ID]
NCT02602535
Trial name or title Mindfulness-oriented recovery enhancement for chronic pain and prescription opioid misuse in primary care
Methods RCT, single-blind
Participants People with chronic pain
Interventions Mindfulness-oriented recovery enhancement vs support group
Outcomes Primary outcomes (baseline to 6 months)
Current Opioid Misuse and/or Addiction Behaviors Checklist and/or urine screen (triangulation aggregate)
- change in opioid misuse
BPI - pain severity and interference
Secondary outcomes
Change in opioid craving
Depression Anxiety Stress Scale
Opioid doses converted into morphine equivalents
Other outcomes
Change in nonreactivity
CSQ
Cognition Emotion Regulation Questionnaire
Ways of Savoring Checklist
Starting date 2016
Contact information Dr Eric Garland, University of Utah
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NCT02602535 (Continued)
Notes clinicaltrials.gov/ct2/show/NCT02602535?term=Mindfulness-Oriented+Recovery+Enhancement&rank=1
NCT02935621
Trial name or title Behavioral interventions for active duty service members and veterans with chronic pain
Methods RCT, single-blind
Participants Active duty service members and veterans with chronic pain conditions
Interventions Mindfulness-oriented recovery enhancement vs support group
Outcomes Primary outcomes (baseline to 6 months)
Current Opioid Misuse and/or Addiction Behaviors Checklist and/or urine screen (triangulation aggregate)
- change in opioid misuse
BPI - pain severity and interference
Secondary outcomes
Change in opioid craving
Depression Anxiety Stress Scal
Opioid doses converted into morphine equivalents
Post-traumatic checklist - military version
Response to Stressful Events Scale
Other outcomes
Change in nonreactivity
CSQ
Cognition Emotion Regulation Questionnaire
Ways of Savoring Checklist
Starting date 2016
Contact information Dr Eric Garland, University of Utah
Notes clinicaltrials.gov/ct2/show/NCT02935621?term=Mindfulness-Oriented+Recovery+Enhancement&rank=4
BPI: Brief Pain Inventory
CSQ: Coping Strategies Questionnaire
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL search strategy
1. MESH DESCRIPTOR Pain EXPLODE ALL TREES
2. MESH DESCRIPTOR Fibromyalgia EXPLODE ALL TREES
3. MESH DESCRIPTOR Headache Disorders EXPLODE ALL TREES
4. MESH DESCRIPTOR Arthritis EXPLODE ALL TREES
5. (((pain* or headache* or migraine* or neuralgia* or neuropath* or arthriti* or osteoarthriti*) not cancer*)):TI,AB,KY
6. #1 OR #2 OR #3 OR #4 OR #5
7. MESH DESCRIPTOR Analgesics, Opioid EXPLODE ALL TREES
8. ((morphine or meperidine or methadone or buprenorphine or fentanyl or hydrocodone or oxycodone or codeine)):TI,AB,KY
9. ((opioid* or opiate* or papaver)):TI,AB,KY
10. MESH DESCRIPTOR Narcotics EXPLODE ALL TREES
11. #7 OR #8 OR #9 OR #10
12. MESH DESCRIPTOR Rehabilitation EXPLODE ALL TREES
13. rehabilitation:TI,AB,KY
14. MESH DESCRIPTOR Opiate Substitution Treatment EXPLODE ALL TREES
15. MESH DESCRIPTOR Narcotic Antagonists EXPLODE ALL TREES
16. ((diprenophine or nalmefene or nalorphine or naloxone or naltrexone or methadone or buprenorphine or clonidine or lofexidine
or guanfacine)):TI,AB,KY
17. MESH DESCRIPTOR Psychotherapy EXPLODE ALL TREES
18. psychotherap*:TI,AB,KY
19. (((cogniti* or behaviour* or behavior* or family or psychosocial*) near5 (therap* or intervention*))):TI,AB,KY
20. ((counsel* or cope or coping)):TI,AB,KY
21. MESH DESCRIPTOR Physical Therapy Modalities EXPLODE ALL TREES
22. MESH DESCRIPTOR Mind-Body Therapies EXPLODE ALL TREES
23. ((physical* near5 therap*)):TI,AB,KY
24. physiotherap*:TI,AB,KY
25. ((biofeedback* or massage* or acupuncture)):TI,AB,KY
26. MESH DESCRIPTOR pastoral care
27. MESH DESCRIPTOR spirituality
28. MESH DESCRIPTOR Adaptation, Psychological
29. ((well being or well-being or relax* or accept* or meditat* or spiritual*)):TI,AB,KY
30. ((withdraw* or wean* or detox* or cease or cessation or reduc* or taper* or stop* or terminat* or remove* or substitu*)):
TI,AB,KY withdraw* or wean* or detox* or cease or cessation or reduc* or taper* or stop* or terminat* or remove* or substitu*
31. #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24
32. #6 AND #11 AND #31
33. MESH DESCRIPTOR Pain, Postoperative EXPLODE ALL TREES
34. #32 NOT #33
MEDLINE search strategy (via Ovid)
1. exp Pain, Intractable/ or exp Chronic Pain/
2. Fibromyalgia/
3. exp Headache Disorders/
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4. exp Arthritis/
5. (pain* or headache* or migraine* or neuralgia* or neuropath* or arthriti* or osteoarthriti*).mp.
6. 1 or 2 or 3 or 4 or 5
7. exp Analgesics, Opioid/
8. (morphine or meperidine or methadone or buprenorphine or fentanyl or hydrocodone or oxycodone or codeine).mp.
9. (opioid* or opiate* or papaver).mp.
10. exp Narcotics/
11. 7 or 8 or 9 or 10
12. exp Rehabilitation/
13. rehabilitation.fs.
14. Opiate Substitution Treatment/
15. exp Narcotic Antagonists/
16. (diprenophine or nalmefene or nalorphine or naloxone or naltrexone or methadone or buprenorphine or clonidine or lofexidine
or guanfacine).mp.
17. exp Psychotherapy/
18. psychotherap*.mp.
19. ((cogniti* or behaviour* or behavior* or family or psychosocial*) adj5 (therap* or intervention*)).mp.
20. (counsel* or cope or coping).mp.
21. exp Physical Therapy Modalities/
22. exp Mind-Body Therapies/
23. (physical* adj5 therap*).mp.
24. physiotherap*).mp.
25. (biofeedback* or massage* or acupuncture).mp.
26. pastoral care/ or spirituality/
27. Adaptation, Psychological/
28. (well being or well-being or relax* or accept* or meditat* or spiritual*).mp.
29. (withdraw* or wean* or detox* or cease or cessation or reduc* or taper* or stop* or terminat* or remove* or substitu*).mp.
30. or/12-29
31. 6 and 11 and 30
32. randomized controlled trial.pt.
33. controlled clinical trial.pt.
34. randomized.ab.
35. placebo.ab.
36. drug therapy.fs.
37. randomly.ab.
38. trial.ab.
39. groups.ab.
40. 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
41. exp animals/ not humans.sh.
42. 40 not 41
43. 31 and 42
44. (post-operative or postoperative).mp.
45. 43 not 44
46. limit 45 to (“young adult (19 to 24 years)” or “adult (19 to 44 years)” or “young adult and adult (19-24 and 19-44)” or “middle
age (45 to 64 years)” or “middle aged (45 plus years)” or “all aged (65 and over)” or “aged (80 and over)”)s)“ or ”all aged (65 and
over)“ or ”aged (80 and over)“)
Embase search strategy (via Ovid)
1. exp chronic pain/ or exp intractable pain/
2. Fibromyalgia/
3. exp Headache Disorders/
4. exp Arthritis/
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5. ((pain* or headache* or migraine* or neuralgia* or neuropath* or arthriti* or osteoarthriti*) not cancer*).mp. [mp=title, abstract,
original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
6. or/1-5
7. exp Analgesics, Opioid/
8. (morphine or meperidine or methadone or buprenorphine or fentanyl or hydrocodone or oxycodone or codeine).mp. [mp=title,
abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier]
9. (opioid* or opiate* or papaver).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
10. exp Narcotics/
11. or/7-10
12. exp Rehabilitation/
13. rehabilitation.fs.
14. Opiate Substitution Treatment/
15. exp Narcotic Antagonists/
16. (diprenorphine or nalmefene or nalorphine or naloxone or naltrexone or methadone or buprenorphine or clonidine or lofexidine
or guanfacine).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier]
17. exp Psychotherapy/
18. psychotherap*.mp.
19. ((cogniti* or behaviour* or behavior* or family or psychosocial*) adj5 (therap* or intervention*)).mp.
20. (counsel* or cope or coping).mp.
21. exp Physical Therapy Modalities/
22. exp Mind-Body Therapies/
23. (physical* adj5 therap*).mp.
24. physiotherap*.mp.
25. (biofeedback* or massage* or acupuncture).mp.
26. pastoral care/ or spirituality/
27. Adaptation, Psychological/
28. (well being or well-being or relax* or accept* or meditat* or spiritual*).mp.
29. (withdraw* or wean* or detox* or cease or cessation or reduc* or taper* or stop* or terminat* or remove* or substitu*).mp.
30. or/12-29
31. 6 and 11 and 30
32. random$.tw.
33. factorial$.tw.
34. crossover$.tw.
35. cross over$.tw.
36. cross-over$.tw.
37. placebo$.tw.
38. (doubl$ adj blind$).tw.
39. (singl$ adj blind$).tw.
40. assign$.tw.
41. allocat$.tw.
42. volunteer$.tw.
43. Crossover Procedure/
44. double-blind procedure.tw.
45. Randomized Controlled Trial/
46. Single Blind Procedure/
47. or/32-46
48. (animal/ or nonhuman/) not human/
49. 47 not 48
50. 31 and 49
29Interventions for the reduction of prescribed opioid use in chronic non-cancer pain (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. Additional data supplied by study authors
Naylor 2010 Baseline Post treatment 4 months 8 months
McGill Typical Pain
TIVR 5.7 ± 1.9 5.5 ± 1.7 4.1 ± 2.2 3.4 ± 2.4
Control 6.8 ± 1.5 5.6 ± 1.6 5.7 ± 1.4 5.7 ± 1.7
BDI
TIVR 16.7 ± 6.5 10.4 ± 6.4 8.1 ± 5.7 8.1 ± 4.8
Control 18.6 ± 11.2 16.7 ± 11.2 16.3 ± 8.3 14.9 ± 8.7
Zheng 2008 Baseline Treatment Post treatment
Weeks 1, 2 Week 5 Week 8 Week 9 Week 12 Week 16 Week 20
Average pain
REA 4.9 ± 1.7 4.1 ± 2.3 4.2 ± 2.3 3.9 ± 1.9 4.0 ± 1.8 3.8 ± 1.7 3.6 ± 1.7
SEA 5.6 ± 1.7 5.1 ± 1.7 5.4 ± 2.4 5.1 ± 2.0 5.3 ± 2.2 5.0 ± 2.0 4.6 ± 2.1
BDI total
REA 18.4 ± 7.1 15.7 ± 9.7 17.1 ± 8.3 Not measured 13.8 ± 8.1 14.1 ± 9.3 14.0 ± 7.5
SEA 19.0 ± 8.3 16.3 ± 10.9 15.3 ± 9.6 Not measured 14.5 ± 10.8 15.2 ± 12.0 14.7 ± 13.2
WH A T ’ S N E W
Last assessed as up-to-date: 4 January 2017.
Date Event Description
17 February 2017 New search has been performed This review has been updated to include the results of
a new search in January 2017. Three new studies were
identified
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(Continued)
17 February 2017 New citation required but conclusions have not
changed
We included three new studies including 192 partici-
pants in this update. Conclusions have not changed
H I S T O R Y
Protocol first published: Issue 1, 2013
Review first published: Issue 9, 2013
Date Event Description
30 March 2016 Amended Contact details amended.
C O N T R I B U T I O N S O F A U T H O R S
Draft the protocol EF/CE
Develop a search strategy CE
Search for studies (usually 2 authors) EF/LH
Obtain copies of studies EF/LH
Select which studies to include (2 + 1 arbiter) EF/LH/CE
Extract data from studies (2 authors) EF/LH
Enter data into RevMan EF
Carry out the analysis N/A
Interpret the analysis All authors
Draft the final write-up of the review EF/CE
Update the review CE
Methodologist name CE
Statistician name Gavin Stewart
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D E C L A R A T I O N S O F I N T E R E S T
CE: none known.
EF: none known.
KHT: none known. KHT is a public health specialist in training who is involved in the planning of health services for patients with
chronic pain.
LH: none known.
SD: none known.
CS: none known. CS is a consultant anaesthetist working in pain management who manages chronic pain patients who are attempting
to reduce prescribed opioids.
RK has attended advisory board meetings, received honoraria or held research grants for Grunenthal (2012 to 2015), Mundipharma
Research (2016 to 2019) and Actavis (2017), who market opioid analgesics.
RAM has received grant support from Grünenthal relating to individual patient-level analyses of trial data regarding tapentadol in
osteoarthritis and back pain (2015). He has received honoraria for attending boards with Menarini concerning methods of analgesic
trial design (2014), with Novartis (2014) about the design of network meta-analyses, and RB on understanding pharmacokinetics of
drug uptake (2015). He has received honoraria from Omega Pharma (2016) and Futura Pharma (2016) for providing advice on trial
and data analysis methods.
S O U R C E S O F S U P P O R T
Internal sources
• Oxford Pain Relief Trust, UK.
Institutional support
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not search PsycLIT in either the first version of this protocol (Windmill 2013) or in this 2017 update, as stated in our protocol,
due to the low yield and duplication between that database and the other databases searched. We contacted the authors of studies
identified for inclusion to obtain additional data relevant to this review not included in the published articles. The original search for
studies was intended to be completed without a time limit, but we limited inclusion to studies published in 2000 and later to reflect
major changes since 2000 in prescribing of opioids to large numbers of people with chronic non-cancer pain; in this way, we worked
to ensure that the review would have contemporary relevance. Although not explicitly stated in our protocol, we excluded studies of
fewer than 10 participants in each treatment arm at post-treatment.
For the 2017 update, it was not possible to undertake planned data synthesis, sub-group analyses, or sensitivity analyses. We added
GRADE assessment methods as is mandatory with Cochrane Reviews, however, it was not possible to conduct these assessments due
to the heterogeneity of the studies. We have also removed ’blinding of personnel and participants’ from the ’Risk of bias’ assessment,
as it is not possible to blind participants or personnel to psychological treatments. We searched trials registries for further trials not
captured by our search method. We amended the first secondary outcome of ’pain intensity’ to ’pain intensity/severity’ for clarity.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Analgesics, Opioid [∗administration & dosage]; Chronic Pain [drug therapy; etiology; ∗therapy]; Cognitive Therapy [∗methods];
Drug Tolerance; Electroacupuncture [∗methods]; Observational Studies as Topic; Randomized Controlled Trials as Topic; Therapy,
Computer-Assisted [methods]
MeSH check words
Humans
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